Gannet BioChem Appointment of Dr. Harry Rathore
Gannet BioChem, a prominent player in the specialty chemical Contract Development and Manufacturing sector, has announced an important addition to its leadership team with the appointment of Dr. Harry Rathore to its Board of Directors. This strategic move follows the recent acquisition by Ampersand Capital Partners, a private equity firm that focuses on fostering growth in life sciences and healthcare.
Dr. Harry Rathore's Extensive Experience
Dr. Harry Rathore brings an impressive blend of over 35 years of experience in specialty chemicals, pharmaceuticals, and Contract Development and Manufacturing Organizations (CDMOs) to Gannet BioChem. He has held significant positions, serving as a Board Member and Strategic Advisor for Ascensus Specialties and VanDeMark, Inc. His prior roles include President and CEO of Callery Inc. as well as executive positions with Lonza AG, Alcami, and Borregaard Synthesis. Notably, he founded PolyOrganix, Inc., a company dedicated to specialty pharmaceuticals and fine chemicals.
Educational Background
Dr. Rathore's academic credentials are as robust as his professional experiences. He earned a Ph.D. in Medicinal Chemistry from Oregon State University. Additionally, he holds both a Master of Science and a Bachelor of Science in Pharmaceutical Sciences from Banaras Hindu University.
Impact on Gannet BioChem's Growth
According to Nick Shackley, CEO of Gannet BioChem, Dr. Rathore's extensive background in the specialty chemical and pharmaceutical fields will significantly contribute to the company’s growth trajectory and innovation. Shackley expressed eagerness to collaborate with Rathore as Gannet executes its strategic plans to expand its reach in the global therapeutics market.
Dr. Rathore's Perspective on the Appointment
Expressing his enthusiasm about joining Gannet BioChem's Board, Dr. Rathore stated, "I am honored to be part of the Board during this crucial phase of the company's evolution. With Gannet's specialized capabilities in PEG reagents, bioconjugation, and GMP manufacturing, we aim to advance the next generation of biopharmaceuticals effectively." His insights will undoubtedly guide Gannet as it navigates future challenges and opportunities.
About Gannet BioChem
Gannet BioChem stands at the forefront of specialty CDMOs, boasting over 30 years of expertise in the development and manufacturing of polyethylene glycol (PEG) reagents, which are vital components in modern biopharmaceutical and therapeutic products. The company operates out of a cutting-edge, FDA-inspected 124,000 sq. ft. facility. Its dedication to end-to-end Good Manufacturing Practice (GMP) production supports both clinical and commercial therapeutics. With a seasoned team and adaptable production capabilities, Gannet BioChem is committed to delivering innovative solutions to meet the dynamic requirements of the global biopharmaceutical industry.
About Ampersand Capital Partners
Ampersand Capital Partners, established in 1988, is a middle-market private equity firm with a focus on growth-oriented investments in the healthcare sector. With $3 billion of assets under management, Ampersand combines private equity and operational strategies to enhance value and foster long-term performance alongside its portfolio companies. The firm has played a pivotal role in building numerous leading companies in its core healthcare sectors.
Frequently Asked Questions
What recent development did Gannet BioChem announce?
Gannet BioChem appointed Dr. Harry Rathore to its Board of Directors.
What experience does Dr. Rathore bring to Gannet BioChem?
Dr. Rathore has over 35 years of experience in specialty chemicals, pharmaceuticals, and CDMOs.
What did the CEO of Gannet BioChem say about Dr. Rathore?
CEO Nick Shackley highlighted that Dr. Rathore's background would provide valuable guidance for the company's growth.
Where is Gannet BioChem located?
Gannet BioChem operates out of a state-of-the-art facility in Huntsville, Alabama.
What does Gannet BioChem specialize in?
The company specializes in developing and manufacturing polyethylene glycol (PEG) reagents for biopharmaceuticals.
